AdvanThink and Inserm UMR_S 999 join forces to revolutionize the discovery of innovative therapeutic targets
Saint-Aubin, March 20, 2024 - The BioAnalysis division ofAdvanThink, a leader in the exploitation and exploration of massive and complex data, announces its partnership with Sylvia Cohen-Kaminsky, CNRS Research Director and Researcher recognized for her work on the theme of Pulmonary Arterial Hypertension (PAH), conducted in the Inserm UMR_S999 unit within the Paris Saclay University innovation ecosystem.
This collaboration, which came into being at the Rendez-vous de Bioanalyse Paris Saclay, is the fruit of in-depth discussions. It aims to exploit and explore the vast quantities of data generated by Sylvia Cohen-Kaminsky and her team in the context of the body of knowledge on PAH, to better understand the pathophysiological positioning of a potential therapeutic target identified in this disease.
Today, only multiomics approaches can provide a detailed understanding of the molecular mechanisms involved in pathologies of multifactorial origin. Transcriptomic, proteomic and lipidomic data have thus been produced as part of this project. Each of these omics dimensions sheds light on certain aspects of the pathology. The challenge, therefore, is to analyze these different types of data in combination, in order to add up the contributions of each of them and ultimately obtain the most holistic view possible of the molecular mechanisms surrounding the potential target identified and their critical aspect in PAH.
PAH, a rare and serious disease with a dismal prognosis, requires significant advances to improve treatment and patients' quality of life. This collaboration thus represents considerable hope for Medical Research, offering a further demonstrator of AdvanThink's AI technologies in the field of BioAnalysis and promising prospects for a better understanding of the disease and the development of new treatments.
The decision to collaborate was taken jointly by Brice Perdrix, CEO of AdvanThink, and Sylvia Cohen-Kaminsky, PhD (DR CNRS), and a partnership agreement was signed with INSERM-Transfert, underlining the commitment of both parties to this innovative initiative.
"PAH is a complex disease, and its molecular mechanisms represent a formidable playground for tackling this challenge with a tool such as our Amadea data science platform. Data Science platform," stresses Jean-Philippe Meyniel, PhD Head of Bio & Health Dept, and Brice Perdrix.
Sylvia Cohen-Kaminsky contributes her critical eye and essential operational expertise to data analysis, with the support of her thesis student, Florent Dumont.
"PAH is a rare disease (48 to 55 cases per million), but not an orphan disease. Several active agents from the vasodilator class are approved and used in bi- or even tri-therapy combinations. They prolong patient survival, but are not curative. Identifying the right targets in a complex molecular network, those central to the mechanism of pulmonary vascular remodeling leading to PAH, is the challenge we're going to take up with AdvanThink," says Sylvia Cohen-Kaminsky .
For its part, AdvanThink provides the technological expertise needed to effectively exploit massive and complex data.
This collaboration is part of a proactive approach aimed at exploring in depth the biological mechanisms involved in PAH, opening up new prospects for the development of innovative treatments.
About the experts :
Jean-Philippe MEYNIEL, PhD: Jean-Philippe MEYNIEL has over 29 years' experience in Health Research. With a PhD in Cell Biology and Physiology, and an engineering degree in Bioinformatics, he has built up a rich career in Research Institutes such as the Institut André Lwoff, in Villejuif, and the Institut Curie, in Paris. At the latter, he worked as a Bioanalyst in the Translational Research Department, and was, among other things, responsible for microarray data analysis. His cutting-edge expertise then led him to join AdvanThink, where he actively contributes to the advancement of projects, thanks to his passion for data and his technical know-how.
Sylvia Cohen-Kaminsky, PhD: Sylvia Cohen-Kaminsky has been Director of Research at CNRS since 2002, where she has made a significant contribution to understanding immune and autoimmune mechanisms. She joined Inserm in 2010, where she coordinates multidisciplinary diagnostic and therapeutic innovation projects in Pulmonary Arterial Hypertension (PAH). With her MBA LS-Lead training, validated at the end of 2020, she is CSO of a Biotech created in 2022, after maturation at SATT Paris Saclay https://www.satt.fr/alsymo/. Her ambitious goal is to lead the clinical development of an innovative drug candidate for PAH, demonstrating her commitment to innovation and improving healthcare.
About AdvanThink and its BioAnalysis division :
A pioneer in Machine Learning since 1990, AdvanThink equips banks and manufacturers in their Data and AI initiatives. FraudManager and Amadea use in-depth data analysis to enable real-time decision-making in the fight against fraud, commercial, marketing and regulatory reporting, and precision operational marketing. Key figures: 60 employees, over 1,000 data & AI projects in production, 60 billion euros secured in real time every day and a bank payment fraud solution used in 178 countries by the biggest banks.
The Bioanalysis Department, staffed by experienced biologists, plays an essential role in the collection, analysis and interpretation of biological data for this project. Their expertise will help inform advances in medical research in the field of PAH.
AdvanThink's customer references include technology platforms, pharmaceutical giants such as Sanofi, innovative biotechs, and prestigious medical biology laboratories such as Bioclinic and Cerba. Our partners include renowned academic research teams such as INRAE, Institut Curie, Institut Pasteur, CNAM, Sorbonne Paris-Université and Université Paris-Saclay, as well as major funders such as the Banque Publique d'Investissement (BPI). This diversity of collaborations testifies to the confidence placed in AdvanThink in the field of Medical Research, where the company is committed to maintaining high quality standards and actively contributing to the advancement of knowledge and the development of new therapies.